New insights into the pathogenesis and therapeutics of episodic ataxia type 1
- PMID: 26347608
- PMCID: PMC4541215
- DOI: 10.3389/fncel.2015.00317
New insights into the pathogenesis and therapeutics of episodic ataxia type 1
Abstract
Episodic ataxia type 1 (EA1) is a K(+) channelopathy characterized by a broad spectrum of symptoms. Generally, patients may experience constant myokymia and dramatic episodes of spastic contractions of the skeletal muscles of the head, arms, and legs with loss of both motor coordination and balance. During attacks additional symptoms may be reported such as vertigo, blurred vision, diplopia, nausea, headache, diaphoresis, clumsiness, stiffening of the body, dysarthric speech, and difficulty in breathing. These episodes may be precipitated by anxiety, emotional stress, fatigue, startle response or sudden postural changes. Epilepsy is overrepresented in EA1. The disease is inherited in an autosomal dominant manner, and genetic analysis of several families has led to the discovery of a number of point mutations in the voltage-dependent K(+) channel gene KCNA1 (Kv1.1), on chromosome 12p13. To date KCNA1 is the only gene known to be associated with EA1. Functional studies have shown that these mutations impair Kv1.1 channel function with variable effects on channel assembly, trafficking and biophysics. Despite the solid evidence obtained on the molecular mechanisms underlying EA1, how these cause dysfunctions within the central and peripheral nervous systems circuitries remains elusive. This review summarizes the main breakthrough findings in EA1, discusses the neurophysiological mechanisms underlying the disease, current therapies, future challenges and opens a window onto the role of Kv1.1 channels in central nervous system (CNS) and peripheral nervous system (PNS) functions.
Keywords: KCNA1; Kv1.1 potassium channel; channelopathy; episodic ataxia type 1; episodic ataxia type 1 therapy; point mutations.
Figures
Similar articles
-
Identification of a New de Novo Mutation Underlying Regressive Episodic Ataxia Type I.Front Neurol. 2018 Jul 25;9:587. doi: 10.3389/fneur.2018.00587. eCollection 2018. Front Neurol. 2018. PMID: 30140249 Free PMC article.
-
Episodic ataxia type 1 mutations in the KCNA1 gene impair the fast inactivation properties of the human potassium channels Kv1.4-1.1/Kvbeta1.1 and Kv1.4-1.1/Kvbeta1.2.Eur J Neurosci. 2006 Dec;24(11):3073-83. doi: 10.1111/j.1460-9568.2006.05186.x. Eur J Neurosci. 2006. PMID: 17156368
-
Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability.Ann Neurol. 2000 Oct;48(4):647-56. Ann Neurol. 2000. PMID: 11026449
-
Kv1.1 Channelopathies: Pathophysiological Mechanisms and Therapeutic Approaches.Int J Mol Sci. 2020 Apr 22;21(8):2935. doi: 10.3390/ijms21082935. Int J Mol Sci. 2020. PMID: 32331416 Free PMC article. Review.
-
Novel Genetic Variants Expand the Functional, Molecular, and Pathological Diversity of KCNA1 Channelopathy.Int J Mol Sci. 2023 May 16;24(10):8826. doi: 10.3390/ijms24108826. Int J Mol Sci. 2023. PMID: 37240170 Free PMC article. Review.
Cited by
-
Kinesigenic Triggers in Episodic Ataxia Type 1.Mov Disord Clin Pract. 2020 Jul 19;7(6):723-724. doi: 10.1002/mdc3.13008. eCollection 2020 Aug. Mov Disord Clin Pract. 2020. PMID: 32775529 Free PMC article. No abstract available.
-
Episodic Ataxia Type 1 (K-channelopathy) Manifesting as Paroxysmal Nonkinesogenic Dyskinesia: Expanding the Phenotype.Mov Disord Clin Pract. 2017 Jul 31;4(5):784-786. doi: 10.1002/mdc3.12518. eCollection 2017 Sep-Oct. Mov Disord Clin Pract. 2017. PMID: 30363417 Free PMC article.
-
An activator of voltage-gated K+ channels Kv1.1 as a therapeutic candidate for episodic ataxia type 1.Proc Natl Acad Sci U S A. 2023 Aug;120(31):e2207978120. doi: 10.1073/pnas.2207978120. Epub 2023 Jul 24. Proc Natl Acad Sci U S A. 2023. PMID: 37487086 Free PMC article.
-
Mutations underlying Episodic Ataxia type-1 antagonize Kv1.1 RNA editing.Sci Rep. 2017 Feb 20;7:41095. doi: 10.1038/srep41095. Sci Rep. 2017. PMID: 28216637 Free PMC article.
-
Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery.Front Pharmacol. 2016 May 10;7:121. doi: 10.3389/fphar.2016.00121. eCollection 2016. Front Pharmacol. 2016. PMID: 27242528 Free PMC article. Review.
References
-
- Bain J. R., Mackinnon S. E., Hudson A. R., Wade J., Evans P., Makino A., et al. . (1992). The peripheral nerve allograft in the primate immunosuppressed with Cyclosporin A: I. Histologic and electrophysiologic assessment. Plast. Reconstr. Surg. 90, 1036–1046. 10.1097/00006534-199212000-00015 - DOI - PubMed
-
- Begum R., Kullmann D. M. (2011). “Altered presynaptic spike properties in cerebellar basket cells in a mouse model of episodic ataxia type 1,” Program No. 447.15/E26, 2011 Neuroscience Meeting Planner, (Washington, DC: Society for Neuroscience; ). Available online at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2773&sKey=2642...
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources